In Q4 2023, Baker Bros. Advisors held 69 positions worth $8.3B. They initiated 5 new positions and exited 24. Their largest holding was INCY ($2.3B). Portfolio value shrank -51.3% versus the prior quarter.
Frequently asked questions
What stocks did Baker Bros. Advisors own in Q4 2023?
Baker Bros. Advisors held 69 biotech stocks in their 13F portfolio in Q4 2023. Their top positions include INCY, BEIGF, ACAD, MDGL, RYTM. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Baker Bros. Advisors's portfolio worth in Q4 2023?
Baker Bros. Advisors's tracked biotech portfolio was worth $8.3B across 69 positions, with total assets under management of approximately $17B. Portfolio values are based on 13F filings with the SEC.
What did Baker Bros. Advisors buy in Q4 2023?
Baker Bros. Advisors initiated 5 new positions in Q4 2023, including CERE, CLDX, NGNE, PFE, TYRA. They also increased 21 existing positions.
What did Baker Bros. Advisors sell in Q4 2023?
Baker Bros. Advisors fully exited 24 positions in Q4 2023, including VERU, BPMC, VSTM, VERA, NKTX and 19 more. They also trimmed 9 existing positions.
Is Baker Bros. Advisors a biotech fund?
Concentrated long-only biotech fund known for taking very large positions in a small number of high-conviction names. The Baker brothers—both trained scientists—focus on deep due diligence of clinical-stage and commercial biotech companies, often holding positions for years through clinical catalysts.
Want AI analysis, insider signals, and catalyst overlays for Baker Bros. Advisors?
View latest Baker Bros. Advisors portfolio →